Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents.

Authors

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center, Houston, TX

Guillermo Garcia-Manero , Charles Alan Schiffer , Lucy A. Godley , Ronald Paquette , Uwe Platzbecker , Paul B. Robbins , Jonathan Norton , Joyson Joseph Karakunnel , Robert Coleman Lindsley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.

First Author: Haruo Iguchi

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.

First Author: Omid Hamid

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

First Author: Naiyer A. Rizvi

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.

First Author: Neil Howard Segal